Travere Therapeutics' market cap has more than doubled in six months, reflecting confidence in FILSPARI's role in treating ...
Travere Therapeutics stock tanked yesterday as the company reported its kidney disease drug FILSPARI had failed to meet its key endpoint in a confirmatory study. TVTX shares fell to ~$8 - down 40% for ...
Travere Therapeutics (TVTX) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to a loss of $0.7 per share a year ago ...
Travere Therapeutics (NASDAQ:TVTX) underwent analysis by 14 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ...
Investor's Business Daily on MSN
Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025
Travere Therapeutics stock has doubled, and then some, in 2025 even as competition heats up for its bread-and-butter drug, ...
Travere Therapeutics’ kidney disease strategy has hit a snag. A pivotal phase 3 trial of sparsentan missed its primary endpoint, but the biotech is undeterred, outlining plans to talk to the FDA about ...
Investors might want to bet on Travere Therapeutics (TVTX), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares ...
Wall Street expects a year-over-year decline in earnings on higher revenues when Travere Therapeutics (TVTX) reports results for the quarter ended September 2023. While this widely-known consensus ...
The latest price target for Travere Therapeutics (NASDAQ:TVTX) was reported by HC Wainwright & Co. on November 28, 2025. The analyst firm set a price target for $47.00 expecting TVTX to rise to within ...
Travere said that Filspari was promising in preserving kidney function. The therapy did not meet all of its endpoints in a phase 3 trial. Travere recently sold two of its drugs for $445 million.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results